ARHGDIG基因在胃癌中的表达特征及预后与免疫浸润相关性研究
Expression Characteristics of ARHGDIG Gene in Gastric Cancer and Its Correlation with Immune Infiltration and Prognosis
DOI: 10.12677/acm.2026.1641243, PDF,   
作者: 胡新宇*, 卢业才#：安徽医科大学第四附属医院胃肠外科，安徽 合肥
关键词: 胃癌；ARHGDIG；生物信息学；免疫浸润；预后；分子机制；Gastric Cancer； ARHGDIG； Bioinformatics； Immune Infiltration； Prognosis； Molecular Mechanism
摘要: 目的：在于探究ARHGDIG基因在胃癌里的表达特征、临床预后价值以及背后可能的分子调控机制，为胃癌的精准诊疗带进新的候选分子靶点。方法：借助TIMER 3.0、UALCAN数据库去分析ARHGDIG在泛癌以及胃癌组织中的差异表达，与肿瘤分期、分级、淋巴结转移这些临床病理特征的相关性。使用GSCA数据库获取ARHGDIG基因甲基化水平与表达量的关联。通过Kaplan-Meier Plotter、GEPIA2数据库来进行生存分析，评估它对胃癌患者总生存期的影响。借助TIMER 3.0分析ARHGDIG与胃癌免疫细胞浸润的关联，并且通过STRING、Metascape数据库筛选相关蛋白质，并开展GO和KEGG通路富集分析。结果：发现ARHGDIG在胃癌组织里表达明显低于癌旁组织，与胃癌的临床病理特征有紧密联系，且ARHGDIG基因甲基化与表达量呈显著负相关。其高表达是胃癌患者预后不好的危险因素，与患者总生存期缩短有明显关联。其次，ARHGDIG表达跟CD4+T细胞浸润正相关，与CD8⁺T细胞、中性粒细胞浸润呈负相关。ARHGDIG的互作蛋白主要富集在Rho蛋白信号转导、Ras等肿瘤相关通路中。结论：ARHGDIG借助调控肿瘤免疫微环境以及相关信号通路来参与胃癌发生发展，能够作为胃癌预后评估的潜在生物标志物以及靶向治疗候选靶点。
Abstract: Objective: To investigate the expression characteristics of ARHGDIG in gastric cancer, its clinical prognostic value, and the underlying potential molecular regulatory mechanisms, thereby providing new candidate molecular targets for the precision diagnosis and treatment of gastric cancer. Methods: Using the TIMER 3.0 and UALCAN databases, we analyzed the differential expression of ARHGDIG in pan-cancer and gastric cancer tissues, and its correlation with clinical-pathological features such as tumor staging, grading, and lymph node metastasis. The association between ARHGDIG gene methylation levels and expression was analyzed using the GSCA database. Survival analysis was performed using Kaplan-Meier Plotter and the GEPIA2 database to evaluate its impact on the overall survival of gastric cancer patients. The association between ARHGDIG and immune cell infiltration in gastric cancer was analyzed using TIMER 3.0, and related proteins were screened through the STRING and Metascape databases, followed by GO and KEGG pathway enrichment analysis. Results: ARHGDIG expression in gastric cancer tissues was significantly lower than that in adjacent normal tissues and was closely associated with the clinical-pathological features of gastric cancer. Moreover, ARHGDIG gene methylation and expression were significantly negatively correlated. High expression of ARHGDIG was a risk factor for poor prognosis in gastric cancer patients and was significantly associated with shortened overall survival. Additionally, ARHGDIG expression was positively correlated with CD4+ T cell infiltration and negatively correlated with CD8+ T cell and neutrophil infiltration. The interacting proteins of ARHGDIG were primarily enriched in tumor-related pathways, such as Rho protein signaling and Ras. Conclusion: ARHGDIG may be involved in the development of gastric cancer by regulating the tumor immune microenvironment and related signaling pathways, and may be a potential biomarker and target for the prognosis evaluation and targeted therapy of gastric cancer.
文章引用：胡新宇, 卢业才. ARHGDIG基因在胃癌中的表达特征及预后与免疫浸润相关性研究[J]. 临床医学进展, 2026, 16(4): 217-226. https://doi.org/10.12677/acm.2026.1641243

参考文献

[1] Matsuoka, T. and Yashiro, M. (2018) Biomarkers of Gastric Cancer: Current Topics and Future Perspective. World Journal of Gastroenterology, 24, 2818-2832. [Google Scholar] [CrossRef] [PubMed]
[2] Chia, N.Y. and Tan, P. (2016) Molecular Classification of Gastric Cancer. Annals of Oncology, 27, 763-769. [Google Scholar] [CrossRef] [PubMed]
[3] Hu, Z., Yang, D., Tang, Y., Zhang, X., Wei, Z., Fu, H., et al. (2019) Five-Long Non-Coding RNA Risk Score System for the Effective Prediction of Gastric Cancer Patient Survival. Oncology Letters, 17, 4474-4486. [Google Scholar] [CrossRef] [PubMed]
[4] Vega, F.M. and Ridley, A.J. (2008) Rho GTPases in Cancer Cell Biology. FEBS Letters, 582, 2093-2101. [Google Scholar] [CrossRef] [PubMed]
[5] Zubor, P., Dankova, Z., Kolkova, Z., Holubekova, V., Brany, D., Mersakova, S., et al. (2020) Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare. Cancers, 12, Article 1292. [Google Scholar] [CrossRef] [PubMed]
[6] Adra, C.N., Iyengar, A.R., Syed, F.A., Kanaan, I.N., Abe, K., Rilo, H.L.R., et al. (1998) Human ARHGDIG, a GDP-Dissociation Inhibitor for Rho Proteins: Genomic Structure, Sequence, Expression Analysis, and Mapping to Chromosome 16p13.3. Genomics, 53, 104-109. [Google Scholar] [CrossRef] [PubMed]
[7] Zalcman, G., Closson, V., Camonis, J., Honoré, N., Rousseau-Merck, M., Tavitian, A., et al. (1996) RhoGDI-3 Is a New GDP Dissociation Inhibitor (GDI). Identification of a Non-Cytosolic GDI Protein Interacting with the Small GTP-Binding Proteins RhoB and RhoG. Journal of Biological Chemistry, 271, 30366-30374. [Google Scholar] [CrossRef] [PubMed]
[8] de León-Bautista, M.P., Cardenas-Aguayo, M.d.C., Casique-Aguirre, D., Almaraz-Salinas, M., Parraguirre-Martinez, S., Olivo-Diaz, A., et al. (2016) Immunological and Functional Characterization of RhoGDI3 and Its Molecular Targets RhoG and RhoB in Human Pancreatic Cancerous and Normal Cells. PLOS ONE, 11, e0166370. [Google Scholar] [CrossRef] [PubMed]
[9] Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R. and Sitarz, R. (2020) Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21, Article 4012. [Google Scholar] [CrossRef] [PubMed]
[10] 徐向上, 曹志新. 精准医学在胃癌中的研究进展[J]. 腹部外科, 2021, 34(1): 4-9.
[11] Morin, A., Cordelières, F.P., Cherfils, J. and Olofsson, B. (2010) RhoGDI3 and RhoG: Vesicular Trafficking and Interactions with the Sec3 Exocyst Subunit. Small GTPases, 1, 142-156. [Google Scholar] [CrossRef] [PubMed]
[12] Mosaddeghzadeh, N. and Ahmadian, M.R. (2021) The RHO Family GTPases: Mechanisms of Regulation and Signaling. Cells, 10, Article 1831. [Google Scholar] [CrossRef] [PubMed]
[13] Manna, S., Mishra, J., Baral, T., Kirtana, R., Nandi, P., Roy, A., et al. (2023) Epigenetic Signaling and Crosstalk in Regulation of Gene Expression and Disease Progression. Epigenomics, 15, 723-740. [Google Scholar] [CrossRef] [PubMed]
[14] Philip, M. and Schietinger, A. (2021) CD8+ T Cell Differentiation and Dysfunction in Cancer. Nature Reviews Immunology, 22, 209-223. [Google Scholar] [CrossRef] [PubMed]
[15] Filep, J.G. and Ariel, A. (2020) Neutrophil Heterogeneity and Fate in Inflamed Tissues: Implications for the Resolution of Inflammation. American Journal of Physiology-Cell Physiology, 319, C510-C532. [Google Scholar] [CrossRef] [PubMed]
[16] Li, Y., Halladay, T. and Yang, L. (2024) Immune Evasion in Cell-Based Immunotherapy: Unraveling Challenges and Novel Strategies. Journal of Biomedical Science, 31, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
[17] Miggelbrink, A.M., Jackson, J.D., Lorrey, S.J., Srinivasan, E.S., Waibl-Polania, J., Wilkinson, D.S., et al. (2021) CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? Clinical Cancer Research, 27, 5742-5752. [Google Scholar] [CrossRef] [PubMed]
[18] Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., et al. (2023) Targeting Small GTPases: Emerging Grasps on Previously Untamable Targets, Pioneered by Kras. Signal Transduction and Targeted Therapy, 8, Article No. 212. [Google Scholar] [CrossRef] [PubMed]
[19] Zhao, Z. and Manser, E. (2005) PAK and Other Rho-Associated Kinases—Effectors with Surprisingly Diverse Mechanisms of Regulation. Biochemical Journal, 386, 201-214. [Google Scholar] [CrossRef] [PubMed]
[20] Filić, V., Mijanović, L., Putar, D., Talajić, A., Ćetković, H. and Weber, I. (2021) Regulation of the Actin Cytoskeleton via Rho GTPase Signalling in Dictyostelium and Mammalian Cells: A Parallel Slalom. Cells, 10, Article 1592. [Google Scholar] [CrossRef] [PubMed]
[21] Ghafouri-Fard, S., Vafaee, R., Shoorei, H. and Taheri, M. (2020) MicroRNAs in Gastric Cancer: Biomarkers and Therapeutic Targets. Gene, 757, Article ID: 144937. [Google Scholar] [CrossRef] [PubMed]

为你推荐